HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that Harel Gadot, CEO, President and Chairman, will be a featured panelist at The Surgical Disruptive Technology Summit, which is part of SAGES NBT Innovation Weekend, taking place February 19-21 in Houston, TX. SAGES’s mission is to innovate, educate and collaborate to improve patient care, and the SAGES NBT Innovation Weekend se ...

International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY® Continues to Gain Commercial Traction and Exposure as Part of Its Limited Market Release (LMR) in the US HINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that LIBERTY was featured at the International Symposium on Endovas ...

Core Insights - Microbot Medical Inc. is participating in the Society of Interventional Oncology (SIO) annual meeting to share insights and experiences regarding its LIBERTY Endovascular Robotic System, which is currently in a limited market release phase [1][2] - The LIBERTY System is the first FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [3][4] - The company aims to accelerate commercial awareness and adoption of the LIBERTY System through direct engagement with interventional oncologists at the conference [1][2] Company Overview - Microbot Medical Inc. focuses on transforming endovascular procedures with advanced robotic technology, highlighted by the LIBERTY Endovascular Robotic System [4] - The company has a strong intellectual property portfolio and is committed to innovation in the medical device sector [4] Market Context - The interventional oncology market is described as a large and expanding multi-billion dollar sector, with increasing procedure volumes driving demand for advanced technologies like LIBERTY [2] - The full market release of the LIBERTY System is planned for April 2026, coinciding with the Society of Interventional Radiology (SIR) conference [3]

Core Insights - Microbot Medical (MBOT) is a robotic medical technology company that has developed LIBERTY, the world's first single-use remotely-operated robotic technology for endovascular interventions, which facilitates minimally invasive procedures and reduces radiation exposure [1] Company Overview - Microbot Medical specializes in robotic medical technology, focusing on innovations that enhance the efficiency and safety of medical procedures [1] Product Development - The LIBERTY system represents a significant advancement in the field of endovascular interventions, allowing for streamlined processes that minimize patient risk and improve outcomes [1]

Core Insights - Microbot Medical Inc. is progressing towards a Full Market Release (FMR) of its LIBERTY® Endovascular Robotic System in Q2 2026, building on positive customer feedback and market enthusiasm [1] - The company achieved significant milestones in 2025, including FDA 510(k) clearance and the initiation of a limited market release [1][4] - The target market for LIBERTY includes approximately 2.5 million peripheral endovascular procedures annually in the U.S. [1] 2025 Operational and Business Achievements - Received FDA clearance for the LIBERTY system, the first single-use, remotely operated robotic system for peripheral endovascular procedures [4] - Launched a Limited Market Release, with Emory University Hospital being the first to adopt the system [4] - Established a commercial leadership team and expanded cross-functional teams to support launch readiness [4] - Presented pivotal trial data showing 100% robotic navigation success and a 92% reduction in radiation exposure [4] - Expanded the intellectual property portfolio with 20 patents granted and 52 applications pending [4] Anticipated 2026 Operational and Commercial Milestones - Full Market Release of the LIBERTY System is set for Q2 2026, coinciding with the Society of Interventional Radiology conference [3][4] - Plans to grow the customer base by attracting early adopters and securing new hospitals for medium-to-high volume procedures [3] - Aims to validate the LIBERTY System's market opportunity by expanding the types of procedures and end-user call points [3] - Establish commercial infrastructure for expansion into international markets [3] - Maintain a strong presence at key medical societies and conferences throughout 2026 [5]

Core Insights - Emory University Hospital has become the first hospital to adopt the LIBERTY Endovascular Robotic System, aligning with its commitment to advancing interventional radiology [1][5] - LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [2][6] - Microbot Medical is collaborating with Emory to establish an Endovascular Robotics Program, aiming to improve patient care in various peripheral intervention procedures [1][3] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with LIBERTY being the first FDA-cleared single-use robotic solution [6] - The company emphasizes innovation and has a strong intellectual property portfolio, positioning itself as a leader in the future of endovascular care [6] Market Strategy - The limited market release of LIBERTY has commenced, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [2] - The adoption of LIBERTY is seen as a significant milestone in the surgical robotic space, reflecting years of dedication and progress by the Microbot team [5]

Financial Performance - The net loss for the three months ended September 30, 2025, was $3,577,000, compared to a net loss of $3,215,000 for the same period in 2024, reflecting a 11.3% increase in losses[13] - For the nine months ended September 30, 2025, the company reported a net loss of $9,678,000, compared to a net loss of $8,051,000 for the same period in 2024, representing an increase in losses of approximately 20.2%[21] - Basic and diluted net loss per share for the nine months ended September 30, 2025, was $0.25, compared to $0.53 for the same period in 2024[13] - The company reported a net loss of $3,577 million for the three months ended September 30, 2025, compared to a net loss of $3,215 million for the same period in 2024[96] - Net loss for the nine months ended September 30, 2025, was $9,678 million, compared to $8,051 million for the same period in 2024, indicating a 20.2% increase in losses[96] Assets and Equity - As of September 30, 2025, total assets increased to $81,760,000 from $6,031,000 as of December 31, 2024[11] - Total shareholders' equity increased to $78,224,000 as of September 30, 2025, compared to $3,530,000 as of December 31, 2024[11] - Total current assets reached $80,785 thousand as of September 30, 2025, compared to $5,819 thousand as of December 31, 2024[11] - The company had cash equivalents and marketable securities totaling approximately $80,158,000 as of September 30, 2025, excluding restricted cash[27] Cash Flow and Liquidity - Cash and cash equivalents rose to $6,704,000, a significant increase from $3,114,000 in the previous year[11] - The net cash flows used in operating activities for the nine months ended September 30, 2025, were $9,288,000, compared to $7,136,000 for the same period in 2024, indicating a 30.2% increase in cash outflows[21] - The company reported financing income of $611,000 for the nine months ended September 30, 2025, compared to $144,000 in the same period of 2024[13] - The company reported an increase in cash, cash equivalents, and restricted cash to $6,758,000 at the end of the period, up from $527,000 at the end of the same period in 2024[21] Share Issuance and Capital Raising - The company issued 13,891,840 shares of common stock and warrants, raising $25,917,000 during the reporting period[17] - The company raised $83,733,000 through the issuance of common stock and warrants during the nine months ended September 30, 2025, compared to $5,104,000 in the same period of 2024[21] - The Company raised approximately $7,000 from a registered direct offering of 4,000,001 shares at $1.75 per share, with related expenses of approximately $690[69] - The Company raised approximately $27,918 in gross proceeds from the exercise of 14,689,228 outstanding preferred investment options during the three months ended September 30, 2025[79] Expenses - Research and development expenses for the nine months ended September 30, 2025, were $4,741,000, slightly higher than $4,646,000 for the same period in 2024[13] - Payroll and payroll-related expenses for the three months ended September 30, 2025, were $2,035 million, up from $1,391 million in 2024[96] - Operating lease expenses for the three months ended September 30, 2025, were $94 thousand, with total lease cost for the nine months at $191 thousand[99] - Share-based compensation for Q3 2025 was $328 million, compared to $283 million in Q3 2024, reflecting a 15.9% increase[96] Legal and Regulatory Matters - The Company settled a lawsuit for $2,154, including a cash payment of $1,100 and 1,005,965 shares of restricted common stock[63] - The company is evaluating the impact of ASU 2024-03, which requires disaggregation of certain expenses in financial statements, effective for annual fiscal years beginning after December 15, 2026[49] Market and Operational Context - The company has not generated any revenues from its operations to date, and it expects to continue incurring additional losses due to ongoing research and development activities[27] - The company is closely monitoring the impact of military operations in Israel on its operations and has not yet experienced any materially adverse effects, but it continues to assess potential risks[30] - The company is focused on developing next-generation robotic endoluminal surgery devices aimed at minimally invasive surgery, leveraging its micro-robotic technologies[23] Royalties and Grants - Microbot Israel received approximately $2,154 in government grants from the IIA for research and development participation since 2013, with a commitment to pay royalties of 3.0% - 5% on future sales[50][51] - The Company is obligated to pay approximately $50 in royalties related to a grant from the Ministry of Economy for the LIBERTY Endovascular Robotic Surgical System, amounting to 3% of future sales[53] - Microbot Israel acquired assets from Nitiloop Ltd. for a total royalty obligation not exceeding $8,000, with a rate of 3% on net revenue from sales of the acquired devices[59][60] Lease Obligations - Total future lease payments as of September 30, 2025, amount to $1,044 million, with total lease liabilities of $899 million after deducting imputed interest of $145 million[99] - The Company issued a bank guarantee of $54 million to secure lease payments for its Israel office[97]

Core Insights - Microbot Medical Inc. has announced the commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, marking a significant milestone in the introduction of single-use robotic systems for peripheral endovascular procedures [1][2] - The Limited Market Release (LMR) will focus on high procedure volume regions to gather real-world insights and prepare for a Full Market Release (FMR) expected at the Society of Interventional Radiology meeting in April 2026 [1][2] Company Developments - The company has established a core commercial team and secured a third-party logistics partner to support the LMR of LIBERTY® [2] - Positive feedback from physicians and hospital administrators has validated the decision to proceed with the limited market release [1][2] Product Overview - LIBERTY® is the first FDA cleared single-use, remotely operated robotic system designed for precision, efficiency, and safety in endovascular procedures [3] - The product is backed by a strong intellectual property portfolio and a commitment to innovation, positioning Microbot Medical as a leader in the endovascular care market [3]

Core Insights - Microbot Medical Inc. is set to exhibit its LIBERTY Endovascular Robotic System at the upcoming Symposium on Clinical Interventional Oncology, marking its first commercial presence post-FDA clearance [1][2] - The company has completed the recruitment of its commercial leadership team in preparation for the limited market launch of the LIBERTY System, expected in Q4 of this year [2][6] Company Developments - The LIBERTY System will be showcased at booth 208, where interventional oncologists can schedule live hands-on demonstrations [2] - Justin Bourne has joined as Regional Sales Director, bringing 20 years of experience in sales leadership within the healthcare industry, previously at Boston Scientific [3] - Dani Kulp has been appointed as Sales Training Director, with over 15 years of experience in medical education and sales training, focusing on endovascular therapies [4] - Xiomara Ortiz has taken on the role of Marketing Communications Manager, leveraging her extensive experience in digital marketing and brand strategy to enhance the company's brand presence [5] Strategic Outlook - The company has secured a logistics partner and is preparing for the limited market launch of the LIBERTY System, indicating strong momentum since receiving FDA clearance [6] - The addition of key commercial team members is aimed at building a solid foundation for both immediate launch plans and long-term commercial strategy [6] Company Background - Microbot Medical Inc. focuses on transforming endovascular procedures through advanced robotic technology, with the LIBERTY System being the first single-use, remotely operated robotic solution designed for precision and safety [7]

Core Insights - Microbot Medical Inc. is set to launch its LIBERTY Endovascular Robotic System in Q4 2025, with a broader release planned for April 2026 during a major conference [1][4] Group 1: Company Overview - Microbot Medical Inc. specializes in innovative medical devices, focusing on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety [4] Group 2: Partnership and Logistics - The company has partnered with a U.S.-based third-party logistics (3PL) provider to support the commercialization of the LIBERTY System, ensuring effective inventory management and customer support [1][2] - The 3PL provider specializes in the medical device industry, allowing the company to leverage its proximity to key markets and maintain inventory in a climate-controlled warehouse [2] Group 3: Operational Strategy - The partnership with an established logistics provider is expected to enhance the company's go-to-market initiatives, making the commercial launch of LIBERTY more efficient [3]